News Archive - Lifecare

Lifecare – Valuation Report of the Sencell technology (CGM) for diabetes

November 1, 2023
Bergen, Norway, November 1st, 2023: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes a new valuation report of Lifecare’s CGM-technology. The report is enclosed here: 231101 Xplico Valuation Report – Lifecare Commissioned by Lifecare, the life science technology valuation-company Xplico has carried out […]
Read more

Confirmation from Norwegian Medicines Agency

October 17, 2023
Bergen, Norway, October 17th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can reveal an important announcement about regulatory confirmation from Norwegian Medicines Agency (Statens Legemiddelverk). In the process of Lifecare’s initial planning and preparations to bring Sencell CGM to the veterinary market, Lifecare […]
Read more

Progress as planned towards ISO 13485 compliance

October 12, 2023
Bergen, Norway, October 12th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) is considered ready for ISO 13485 audit. ISO 13485 is a Quality Management System specific to medical devices and covers the entire life cycle of […]
Read more

Purchase software for automated production

October 2, 2023
Lifecare has now placed the purchase order for automated production software. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of August 20th 2023 and later investor communication. The launch of an automated production line by end of Q2 2024 is set as a major milestone. To accomplish this, […]
Read more

Sanofi Product Development Agreement Update

September 27, 2023
Reference is made to previous investor communication, i.e. September 23, 2021 and later. Lifecare is engaged with Sanofi in a Product Development Agreement aimed at advancing the miniaturization of Lifecare’s sensor technology for integration into Lifecare’s Sencell Continuous Glucose Monitoring system. Under the terms of the agreement, Sanofi has committed to provide funding contributions, supporting […]
Read more

Presentation – Company update at Redeye Medtech & Diagnostics Seminar

September 26, 2023
Lifecare participated at Redeye Medtech & Diagnostics Seminar. Lifecare presented the latest developments from the company at the Redeye Medtech & Diagnostics Seminar. The presentation was live broadcasted and can be watched at https://www.redeye.se/events/904816/redeye-theme-medtech-diagnostics-2 You also find the company presentation here: Lifecare presentation at Redeye 26th of Sept
Read more

Lifecare announces presentation of additional clinical data from study LFS-SEN-001

September 22, 2023
Lifecare announce today that additional clinical data from study LFS-SEN-001 will be presented at the upcoming international diabetes conference hosted by the Diabetes Technology Society. Lifecare CSO, Professor Dr. Dr. Med. Andreas Pfützner has received an invitation to present the poster “Continuous Glucose Monitoring with an Osmotic-Pressure Based Continuous Glucose Sensor: Results of the First […]
Read more

Lifecare Semi Annual report: Towards market readiness

August 23, 2023
Lifecare has shown major progress in our plan to bring the smallest Continuous Glucose Monitor (CGM) system to the market. Testing in live tissue, implementation of Quality Management System and set up of manufacturing capabilities form the three main pillars in our market-oriented development. – The results from studies concluded in 1H 2023 and the […]
Read more

Lifecare sensor longevity experiment concluded: 6 months operational lifetime

July 18, 2023
Lifecare’s Sencell Continuous Glucose Monitoring (CGM) sensor has reached an operational lifetime of more than 24 weeks (172 days), with a sensor chemistry shelf life of almost 27 weeks (187 days). This achievement confirms the Sencell CGM technology potential and validates Lifecares expectation of a minimum 6-month sensor longevity. The longevity results were achieved by […]
Read more

Proof-of-Concept Study Results presented at American Diabetes Association Scientific Session 2023

June 26, 2023
Data from Lifecare’s Clinical Development Study LFC-SEN-001 was presented at the American Diabetes Association (ADA) Scientific Sessions 2023. Lifecare’s poster presentation reveals the study background, methods, and results. The results include an impressive mean average of absolute error (MARD) of 9,6%, positioning Lifecares’s Sencell technology with an accuracy that is acceptable for therapeutic (medical) decisions […]
Read more